Table 1

Antiangiogenic activity of various drugs, significance of differences, and toxicity

DrugDose/course (μmol/kg)% of inhibition of angiogenesisaSignificance of differencesb (P)Weight change (%)cNo. of deaths/total no. per group
9-AC1.3812.4NS+9.10/7
2.7518.2NS+2.10/7
4.1330.90.075−0.60/6
25.5NS0.00/7
34.20.039−5.80/7
5.5148.80.013−13.00/7
10.0NS−8.50/7
6.8972.5<0.001−26.30/6
47.20.001−16.00/7
67.2<0.001−18.90/7
8.2649.40.001−18.40/7
9.6481.3<0.001−27.30/6
58.5<0.001−21.32/7
12.492.2<0.001−40.02/6
66.5<0.001−20.61/7
TTN3.5639.70.013−7.80/7
5.9318.6NS+4.70/7
38.40.02−9.80/7
8.3152.4<0.001−12.50/7
40.00.015−17.80/7
10.742.90.009−26.40/7
13.148.60.001−21.80/7
15.478.8<0.001−24.50/7
61.6<0.001−12.50/7
17.864.0<0.001−22.51/7
CPT-1151.314.8NS+1.70/6
4.5NS+1.50/7
103.011.4NS−0.60/6
205.08.5NS+6.50/7
46.5NS−3.00/6
256.025.1NS+6.50/7
308.042.5NS+9.20/7
359.045.30.027+12.10/7
Vincristine1.0843.5NS−8.20/7
2.7149.90.022−6.12/7
3.7953.1NS−30.04/7
4.8851.00.014−11.61/7
  • a Inhibition of angiogenesis in cornea of drug-treated mice, relative to angiogenesis of control placebo-treated mice, equal to 100%.

  • b Significance calculated using Dunnett’s method (see “Materials and Methods”). NS, not significant with P ≥ 0.05.

  • c The difference (in %) between the average body weight on day 0 and day 6 of a treatment course.